Tigulixostat
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Tigulixostat
- Molecular weight
- 294.31
- Structure (SMILES)
- CC(C)n1cc(C#N)c2cc(-n3cc(C(=O)O)cn3)ccc21
- lc 350189
- LC-350189
- lc350189
- Lc350189
- LC350189
- LC350189 200 mg
- LC350189 200mg
- LC350189 600mg
- LC350189 Capsule
- LC350189 Tablet
- tigulixostat
- Tigulixostat
- tigulixostat [INN]
- Tigulixostat [WHO-DD]
- tigulixostat inn
- tigulixostat who dd
- CAS registry numbers
- 1287766-55-5
- ChEMBL ID
- CHEMBL3652780
- InChIKey
- JLQQRYOWGCIMMZ-UHFFFAOYSA-N
- PubChem compound IDs
- 51039100
- FDA ingredient codes (UNII)
- WZ0PYQ6VLU
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -stat
- Condition identifier
- EFO_0004274
- Highest recorded phase
- 1
- Condition identifier
- EFO_0009104
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005393
- Highest recorded phase
- 3
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 1
- Polar surface area
- 83.84
- Calculated partition coefficient (ALogP)
- 2.98
- Calculated partition coefficient (XLogP)
- 1.9
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 22
- Molecular formula
- C16H14N4O2
- Monoisotopic mass
- 294.11167570
- Natural product
- No
- Recorded assays
- 2
- Active assays
- 2
Active assay types
- Confirmatory
Related records
Trials (10)
- A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
- Effect of Tigulixostat on the Pharmacokinetics of Theophylline
- Mass Balance Study of [14C]LC350189 in Healthy Volunteers
- Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults
- Renal PK Study of LC350189
- Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189
- Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects
- Tigulixostat (IBI128) vs Febuxostat in Gout
- Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
- Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
In development for (1)
- Gout Phase 1